Loading clinical trials...

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979•Loma Linda University

View on ClinicalTrials.gov

Summary

This study is to determine if Viagra is effective in reducing dyskinesias in patients with Parkinson's Disease.

Detailed Description

Inclusion Criteria: 1. Diagnosis of idiopathic Parkinson's disease. 2. Age \> 40 years. 3. willingness and ability to comply with the study requirements and give informed consent.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0.
•2. Presence of drug-induced dyskinesias
•3. Age\>40 years.
•4. Willingness and ability to comply with the study requirements and give informed consent.

Exclusion Criteria

•1. Atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or degenerative diseases.
•2. History of stereotaxic brain surgery.
•3. Clinical history of dementia.
•4. Known major psychiatric disorder, major depression, schizophrenia. Known alcoholism or substance dependence within previous 12 months.
•5. History of major hematological, renal, or hepatic abnormalities.
•6. Known coronary artery disease including angina or myocardial infarction within the last 6 months. Significant cardiovascular disease including cardiac failure, unstable angina or life-threatening arrhythmia within the last 6 months.
•7. History of stroke within the last 6 months.
•8. Abnormal EKG consistent with cardiac ischemia.
•9. Treatment with nitrates. Nitrates or any NO donors in any dosage form (oral, sublingual, transdermal, inhalation, or aerosols).
•10. Malignant hypertension or SBP . 180 or \<90, or DBP .110 or \<50.
+8 more criteria

Locations (1)

Loma Linda University

Loma Linda, California, United States

Key Dates

Start Date

February 1, 2002

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

March 30, 2018

Enrollment

ACTUAL participants

Conditions

Parkinson's Disease

Interventions

sildenafil

DRUG

Placebo

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 30, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Deep Brain Stimulation Therapy in Movement Disorders

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations